{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:39:16Z","timestamp":1783463956630,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"DOI":"10.7759\/cureus.98243","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T15:52:52Z","timestamp":1764604372000},"source":"Crossref","is-referenced-by-count":1,"title":["Overview of Huntington\u2019s Disease and Emerging Treatment Strategies: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Alexis J","family":"Vega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel V","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearse A","family":"O'Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor J","family":"Robin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda N","family":"Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Shekoohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Huntington's disease","author":"Harper PS","year":"2002","unstructured":"Harper PS. Huntington's disease. Bates G, Harper P, Jones L (ed): Oxford University Press, Oxford, UK; 2002."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13123437","article-title":"Risk factors and interventions for suicide in Huntington\u2019s disease-a systematic review","volume":"13","author":"Grimaldi A","year":"2024","unstructured":"Grimaldi A, Veneziani I, Culicetto L, Quartarone A, Lo Buono V. Risk factors and interventions for suicide in Huntington\u2019s disease-a systematic review. J Clin Med. 2024, 13:3437. 10.3390\/jcm13123437","journal-title":"J Clin Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"60","author":"ME MacDonald","year":"2017","unstructured":"ME MacDonald, CM Ambrose, MP Duyao, et al.. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 2017, 60:1067-77. 10.1016\/0092-8674(93)90585-E","journal-title":"Cell"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington disease","volume":"1","author":"Bates GP","year":"2015","unstructured":"Bates GP, Dorsey R, Gusella JF, et al.. Huntington disease. Nat Rev Dis Primers. 2015, 1:15005. 10.1038\/nrdp.2015.5","journal-title":"Nat Rev Dis Primers"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29228","article-title":"Prevalence and incidence of Huntington's disease: an updated systematic review and meta-analysis","volume":"37","author":"Medina A","year":"2022","unstructured":"Medina A, Mahjoub Y, Shaver L, Pringsheim T. Prevalence and incidence of Huntington's disease: an updated systematic review and meta-analysis. Mov Disord. 2022, 37:2327-35. 10.1002\/mds.29228","journal-title":"Mov Disord"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25075","article-title":"The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis","volume":"27","author":"Pringsheim T","year":"2012","unstructured":"Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N. The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis. Mov Disord. 2012, 27:1083-91. 10.1002\/mds.25075","journal-title":"Mov Disord"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-801893-4.00001-8","article-title":"Genetics of Huntington disease","volume":"144","author":"Nance MA","year":"2017","unstructured":"Nance MA. Genetics of Huntington disease. Handb Clin Neurol. 2017, 144:3-14. 10.1016\/B978-0-12-801893-4.00001-8","journal-title":"Handb Clin Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddab170","article-title":"Huntington's disease: nearly four decades of human molecular genetics","volume":"30","author":"Gusella JF","year":"2021","unstructured":"Gusella JF, Lee JM, MacDonald ME. Huntington's disease: nearly four decades of human molecular genetics. Hum Mol Genet. 2021, 30:254-63. 10.1093\/hmg\/ddab170","journal-title":"Hum Mol Genet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.tig.2004.01.008","article-title":"Huntingtin-protein interactions and the pathogenesis of Huntington's disease","volume":"20","author":"Li SH","year":"2004","unstructured":"Li SH, Li XJ. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet. 2004, 20:146-54. 10.1016\/j.tig.2004.01.008","journal-title":"Trends Genet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0b013e3283550c97","article-title":"Huntington's disease","volume":"25","author":"Ha AD","year":"2012","unstructured":"Ha AD, Fung VS. Huntington's disease. Curr Opin Neurol. 2012, 25:491-8. 10.1097\/WCO.0b013e3283550c97","journal-title":"Curr Opin Neurol"},{"key":"ref11","article-title":"Huntington disease","author":"Ajitkumar A","year":"2025","unstructured":"Ajitkumar A, De Jesus O. Huntington disease. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref12","article-title":"Chorea","author":"Lui F","year":"2025","unstructured":"Lui F, Merical B, S\u00e1nchez-Manso JC. Chorea. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.71476","article-title":"Efficacy and safety of tetrabenazine in reducing chorea and improving motor function in individuals with Huntington\u2019s disease: a systematic review","volume":"16","author":"Vadlamani N","year":"2024","unstructured":"Vadlamani N, Ibrahimli S, Khan FA, Castillo JA, Amaravadi KS, Nalisetty P, Khan S. Efficacy and safety of tetrabenazine in reducing chorea and improving motor function in individuals with Huntington\u2019s disease: a systematic review. Cureus. 2024, 16:71476. 10.7759\/cureus.71476","journal-title":"Cureus"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168363","article-title":"New avenues for the treatment of Huntington\u2019s disease","volume":"22","author":"Kim A","year":"2021","unstructured":"Kim A, Lalonde K, Truesdell A, Gomes Welter P, Brocardo PS, Rosenstock TR, Gil-Mohapel J. New avenues for the treatment of Huntington\u2019s disease. Int J Mol Sci. 2021, 22:8363. 10.3390\/ijms22168363","journal-title":"Int J Mol Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2019.01.039","article-title":"Huntingtin lowering strategies for disease modification in Huntington\u2019s disease","volume":"101","author":"Tabrizi SJ","year":"2019","unstructured":"Tabrizi SJ, Ghosh R, Leavitt BR. Huntingtin lowering strategies for disease modification in Huntington\u2019s disease. Neuron. 2019, 101:801-19. 10.1016\/j.neuron.2019.01.039","journal-title":"Neuron"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101385","article-title":"Gene targeting techniques for Huntington's disease","volume":"70","author":"Fields E","year":"2021","unstructured":"Fields E, Vaughan E, Tripu D, et al.. Gene targeting techniques for Huntington's disease. Ageing Res Rev. 2021, 70:101385. 10.1016\/j.arr.2021.101385","journal-title":"Ageing Res Rev"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2009.03.004","article-title":"A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference","volume":"217","author":"Lombardi MS","year":"2009","unstructured":"Lombardi MS, Jaspers L, Spronkmans C, et al.. A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference. Exp Neurol. 2009, 217:312-9. 10.1016\/j.expneurol.2009.03.004","journal-title":"Exp Neurol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2007.116","article-title":"Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts","volume":"19","author":"van Bilsen PH","year":"2008","unstructured":"van Bilsen PH, Jaspers L, Lombardi MS, Odekerken JC, Burright EN, Kaemmerer WF. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts. Hum Gene Ther. 2008, 19:710-9. 10.1089\/hum.2007.116","journal-title":"Hum Gene Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00121-1","article-title":"Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities","volume":"21","author":"Tabrizi SJ","year":"2022","unstructured":"Tabrizi SJ, Estevez-Fraga C, van Roon-Mom WM, et al.. Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities. Lancet Neurol. 2022, 21:645-58. 10.1016\/S1474-4422(22)00121-1","journal-title":"Lancet Neurol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/11.23.2905","article-title":"Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells","volume":"11","author":"Yang W","year":"2002","unstructured":"Yang W, Dunlap JR, Andrews RB, Wetzel R. Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum Mol Genet. 2002, 11:2905-17. 10.1093\/hmg\/11.23.2905","journal-title":"Hum Mol Genet"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2019.1631161","article-title":"Emerging therapies in Huntington's disease","volume":"19","author":"Bashir H","year":"2019","unstructured":"Bashir H. Emerging therapies in Huntington's disease. Expert Rev Neurother. 2019, 19:983-95. 10.1080\/14737175.2019.1631161","journal-title":"Expert Rev Neurother"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1524575113","article-title":"Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis","volume":"113","author":"Wang G","year":"2016","unstructured":"Wang G, Liu X, Gaertig MA, Li S, Li XJ. Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis. Proc Natl Acad Sci U S A. 2016, 113:3359-64. 10.1073\/pnas.1524575113","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-022-03150-5","article-title":"CRISPR\/Cas9 mediated therapeutic approach in Huntington\u2019s disease","volume":"60","author":"Alkanli SS","year":"2023","unstructured":"Alkanli SS, Alkanli N, Ay A, Albeniz I. CRISPR\/Cas9 mediated therapeutic approach in Huntington\u2019s disease. Mol Neurobiol. 2023, 60:1486-98. 10.1007\/s12035-022-03150-5","journal-title":"Mol Neurobiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-0389-4","article-title":"Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities","volume":"16","author":"Tabrizi SJ","year":"2020","unstructured":"Tabrizi SJ, Flower MD, Ross CA, Wild EJ. Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. Nat Rev Neurol. 2020, 16:529-46. 10.1038\/s41582-020-0389-4","journal-title":"Nat Rev Neurol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-019-0302-7","article-title":"Mechanisms and disease implications of sirtuin-mediated autophagic regulation","volume":"51","author":"Lee IH","year":"2019","unstructured":"Lee IH. Mechanisms and disease implications of sirtuin-mediated autophagic regulation. Exp Mol Med. 2019, 51:1-11. 10.1038\/s12276-019-0302-7","journal-title":"Exp Mol Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2559","article-title":"Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway","volume":"18","author":"Jeong H","year":"2011","unstructured":"Jeong H, Cohen DE, Cui L, et al.. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat Med. 2011, 18:159-65. 10.1038\/nm.2559","journal-title":"Nat Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.47526","article-title":"Huntington's disease: understanding its novel drugs and treatments","volume":"15","author":"Dhingra H","year":"2023","unstructured":"Dhingra H, Gaidhane SA. Huntington's disease: understanding its novel drugs and treatments. Cureus. 2023, 15:47526. 10.7759\/cureus.47526","journal-title":"Cureus"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2014.10.016","article-title":"Generation of human striatal neurons by microRNA-dependent direct conversion of fibroblasts","volume":"84","author":"Victor MB","year":"2014","unstructured":"Victor MB, Richner M, Hermanstyne TO, et al.. Generation of human striatal neurons by microRNA-dependent direct conversion of fibroblasts. Neuron. 2014, 84:311-23. 10.1016\/j.neuron.2014.10.016","journal-title":"Neuron"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108373","article-title":"Molecular mechanisms of ferroptosis and their involvement in brain diseases","volume":"244","author":"Costa I","year":"2023","unstructured":"Costa I, Barbosa DJ, Benfeito S, et al.. Molecular mechanisms of ferroptosis and their involvement in brain diseases. Pharmacol Ther. 2023, 244:108373. 10.1016\/j.pharmthera.2023.108373","journal-title":"Pharmacol Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s12017-018-8518-6","article-title":"The emerging roles of ferroptosis in Huntington's disease","volume":"21","author":"Mi Y","year":"2019","unstructured":"Mi Y, Gao X, Xu H, Cui Y, Zhang Y, Gou X. The emerging roles of ferroptosis in Huntington's disease. Neuromolecular Med. 2019, 21:110-9. 10.1007\/s12017-018-8518-6","journal-title":"Neuromolecular Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.14802\/jmd.21006","article-title":"Gene therapy for Huntington's disease: the final strategy for a cure?","volume":"15","author":"Byun S","year":"2022","unstructured":"Byun S, Lee M, Kim M. Gene therapy for Huntington's disease: the final strategy for a cure?. J Mov Disord. 2022, 15:15-20. 10.14802\/jmd.21006","journal-title":"J Mov Disord"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/417174-overview-of-huntingtons-disease-and-emerging-treatment-strategies-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T15:52:53Z","timestamp":1764604373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/417174-overview-of-huntingtons-disease-and-emerging-treatment-strategies-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.98243","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}